Horizon’s CEO spoke with The Washington Times about today’s release of the ten drugs subject to Medicare price negotiations.
““It’s all wine and roses today — there’s no downside. What we know is there will be reduced investment and drug products pulled,” said Joel White, CEO of Horizon Government Affairs who played a role in creating the Part D program as a key congressional staffer in 2001-03.
Mr. White said Part D’s authors crafted a noninterference clause to prevent a political administration from picking winners and losers in the Medicare drug program.
“Here we have politicians, bureaucrats and lobbyists making decisions about what’s going to get on a list and be price-controlled,” he said. “When you have a product that has likely competition in the future and you have a high-spend product in Medicare that doesn’t make it on the list, there is a decision made.””